Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 2, 2026Thoracic CancerOpen Access

Advanced Thymoma and Advanced Thymic Carcinoma Treatment Practices in 2018–2022: A Nationwide Analysis in Japan

View Full Paper
Ask AI
Bookmark
Share

Authors

JIJunichi IshigakiRRRyoko RikitakeHKHidenori Kage

Discussion

Loading...

Member takes

Overview

Nationwide analysis reports treatment trends for advanced thymoma and thymic carcinoma in Japan, indicating shifting practices.

Key Points

  • This study investigates treatment practices and clinical characteristics of advanced thymoma and thymic carcinoma in Japan.
  • Analyzed data from the Hospital-based Cancer Registry and Diagnosis Procedure Combination survey between 2018 and 2022.
  • Evaluated treatment practices for Stage III and IV thymoma and thymic carcinoma.
  • 556 stage III thymoma, 312 stage III thymic carcinoma, 431 stage IV thymoma, and 976 stage IV thymic carcinoma cases identified.
  • Postoperative radiotherapy was more common for stage III thymic carcinoma (34.1%) than for thymoma (10.7%).
  • Adriamycin-cisplatin-vincristine-cyclophosphamide was used in 41.8% of stage IV thymoma cases, while 99.5% of stage IV thymic carcinoma patients received carboplatin-paclitaxel.

Cite This Study

Ishigaki et al. (2026) studied this question.

synapsesocial.com/papers/6a6eeaaf1b0468a7eeab30fehttps://doi.org/10.1111/1759-7714.70367
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Establishing a Quality Measurement System for Cancer Care in Japan2013 · 31 citations
  2. 2A phase-II trial of dose-dense chemotherapy in patients with disseminated thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9605)2009 · 41 citations